Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/9 cls
Allergan (AGN) Leerink Gary Nachman Other Market outperform -2% $65.78
Nachman raised his FY07 and FY08 revenue estimates to $3.83B from $3.77B and to $4.3B from $4.23B, respectively, after AGN's earnings news (see "EPS Watch," A17).
Allos (ALTH) JMP Securities Charles Duncan Upgrade Strong buy (from market outperform) 5% $5.92
Duncan expects pralatrexate (PDX) will have positive results in the Phase II PROPEL trial to treat relapsed or refractory peripheral T cell lymphoma (PTCL). He expects the study of the small molecule dihydrofolate reductase (DHFR) inhibitor to be complete in 2Q08.
Altus (ALTU) Collins Stewart Andrew Fein Price target Buy -15% $11.91
Fein raised his target to $23 from $21. He believes Genentech (DNA) will license ex-U.S. rights to ALTU's ALTU-238 by year end. Last year, DNA licensed North American rights to the subcutaneous long-acting formulation of somatropin recombinant human growth hormone (see BioCentury, Jan. 1).

Read the full 1601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers